When assessed in fluorescence-based DCDFA assays, we observed that PDA cells lacking ERO1α displayed substantially reduced ability to generate ROS, exhibiting only 66% of the ROS capacity detected in WT tumor cells (Figure 5B and 5C). Here, ERO1A is linked to Patent ductus arteriosus.